On September 25, 2023, Jin Medical International Ltd. Received A Letter From The Listing Qualifications Department Of The Nasdaq Indicating That The Co Was Not In Compliance With Listing Rule 5550(a)(3)

Jin Medical International Ltd. -4.32%

Jin Medical International Ltd.




- SEC Filing

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard


On September 25, 2023, Jin Medical International Ltd. (the "Company") received a letter from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") indicating that the Company was not in compliance with Listing Rule 5550(a)(3), which requires the Company to have at least 300 public holders for continued listing by Nasdaq. On December 18, 2023, the Company received a letter (the "Delisting Letter") from Nasdaq notifying the Company that it had failed to provide a detailed plan to support a decision for further time for compliance. Additionally, Nasdaq staff (the "Staff") determined that the Company did not meet the 300 Round Lot Holder requirement for initial listing on the Nasdaq Capital Market. Nasdaq Staff has determined to initiate procedures to delist the Company's securities from Nasdaq. Unless the Company requests an appeal of that determination, trading of the Company's ordinary shares will be suspended at the opening of business on December 28, 2023.

The Company has submitted a request for a hearing before the Nasdaq Hearings Panel (the "Panel"), which request will stay the suspension of the Company's securities pending the Panel's decision. Subsequently on December 20, 2023, the Company received a letter from Nasdaq indicating that the delisting action has been stayed, pending a final written decision by the Panel. The hearing before the Panel will be held on March 14, 2024. At the hearing, the Company must demonstrate its ability to regain compliance with the particular deficiencies cited by Staff, as well as its ability to sustain long-term compliance with all applicable maintenance criteria.

The Company is presently conducting an internal review with its management and external advisors and is exploring various remedial actions to regain compliance with the requirements set out above.

If at any point before the hearing the Company believes it has regained compliance with all criteria for continued listing, the Company will notify Nasdaq Staff and also inform the Hearings Department. If Nasdaq Staff determines that the Company has regained compliance, the Hearings Department will advise the Company by letter that the hearing is cancelled.

Every question you ask will be answered
Scan the QR code to contact us
Also you can contact us via